Grifols Past Earnings Performance
Past criteria checks 1/6
Grifols's earnings have been declining at an average annual rate of -38.9%, while the Biotechs industry saw earnings growing at 16.1% annually. Revenues have been growing at an average rate of 6.4% per year. Grifols's return on equity is 2.3%, and it has net margins of 0.9%.
Key information
-38.9%
Earnings growth rate
-30.0%
EPS growth rate
Biotechs Industry Growth | -7.2% |
Revenue growth rate | 6.4% |
Return on equity | 2.3% |
Net Margin | 0.9% |
Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?
Apr 20Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 04Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive
Mar 01Does Grifols (BME:GRF) Have A Healthy Balance Sheet?
Feb 20Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price
Jan 09Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load
Nov 10Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value
Oct 20Is Grifols (BME:GRF) A Risky Investment?
Aug 03Calculating The Fair Value Of Grifols, S.A. (BME:GRF)
May 18Is Grifols (BME:GRF) Using Too Much Debt?
Apr 30Grifols (BME:GRF) Seems To Be Using A Lot Of Debt
Nov 18An Intrinsic Calculation For Grifols, S.A. (BME:GRF) Suggests It's 45% Undervalued
Oct 26Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load
Aug 18Revenue & Expenses BreakdownBeta
How Grifols makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 6,592 | 59 | 1,367 | 395 |
30 Sep 23 | 6,535 | 23 | 1,343 | 388 |
30 Jun 23 | 6,479 | 8 | 1,336 | 393 |
31 Mar 23 | 6,358 | 47 | 1,345 | 390 |
31 Dec 22 | 6,064 | 208 | 1,190 | 361 |
30 Sep 22 | 5,549 | 149 | 1,138 | 353 |
30 Jun 22 | 5,207 | 66 | 1,122 | 358 |
31 Mar 22 | 5,016 | 112 | 1,064 | 359 |
31 Dec 21 | 4,933 | 189 | 1,062 | 355 |
30 Sep 21 | 5,044 | 361 | 1,046 | 337 |
30 Jun 21 | 5,199 | 667 | 1,008 | 311 |
31 Mar 21 | 5,231 | 562 | 992 | 298 |
31 Dec 20 | 5,340 | 619 | 986 | 294 |
30 Sep 20 | 5,392 | 687 | 971 | 288 |
30 Jun 20 | 5,353 | 557 | 976 | 286 |
31 Mar 20 | 5,235 | 697 | 959 | 281 |
31 Dec 19 | 5,099 | 625 | 943 | 276 |
30 Sep 19 | 4,961 | 552 | 923 | 271 |
30 Jun 19 | 4,790 | 565 | 878 | 261 |
31 Mar 19 | 4,620 | 568 | 859 | 249 |
31 Dec 18 | 4,487 | 597 | 815 | 241 |
30 Sep 18 | 4,332 | 699 | 777 | 212 |
30 Jun 18 | 4,246 | 704 | 804 | 215 |
31 Mar 18 | 4,279 | 672 | 800 | 219 |
31 Dec 17 | 4,318 | 663 | 860 | 225 |
30 Sep 17 | 4,348 | 571 | 857 | 230 |
30 Jun 17 | 4,291 | 559 | 827 | 222 |
31 Mar 17 | 4,153 | 554 | 810 | 209 |
31 Dec 16 | 4,050 | 545 | 775 | 198 |
30 Sep 16 | 4,014 | 537 | 771 | 216 |
30 Jun 16 | 3,986 | 535 | 776 | 218 |
31 Mar 16 | 3,985 | 529 | 768 | 221 |
31 Dec 15 | 3,935 | 532 | 736 | 224 |
30 Sep 15 | 3,789 | 533 | 696 | 211 |
30 Jun 15 | 3,645 | 507 | 686 | 199 |
31 Mar 15 | 3,466 | 478 | 666 | 194 |
31 Dec 14 | 3,355 | 470 | 661 | 181 |
30 Sep 14 | 3,133 | 417 | 647 | 161 |
30 Jun 14 | 2,972 | 388 | 614 | 150 |
31 Mar 14 | 2,856 | 376 | 584 | 132 |
31 Dec 13 | 2,742 | 346 | 558 | 123 |
30 Sep 13 | 2,708 | 326 | 558 | 124 |
30 Jun 13 | 2,685 | 306 | 551 | 124 |
Quality Earnings: GRF has high quality earnings.
Growing Profit Margin: GRF's current net profit margins (0.9%) are lower than last year (3.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GRF's earnings have declined by 38.9% per year over the past 5 years.
Accelerating Growth: GRF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GRF had negative earnings growth (-71.5%) over the past year, making it difficult to compare to the Biotechs industry average (-2.9%).
Return on Equity
High ROE: GRF's Return on Equity (2.3%) is considered low.